Enterprise Value

1.589B

Cash

325.9M

Avg Qtr Burn

N/A

Short % of Float

13.12%

Insider Ownership

1.47%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Exparel (bupivacaine liposome) Details
Post operative acute pain

Approved

Quarterly sales

Exparel (bupivacaine liposome) Details
Post operative acute pain

Approved

Quarterly sales

Phase 1

Data readout

PCRX-301 (FX301) (NaV1.7 inhibitor) Details
Post operative acute pain , Pain

Failed

Discontinued